The NIH is considering a catastrophic cut to indirect cost reimbursements for public universities, which would hurt the ...

Funding medical research is about more than just numbers. It's real people,” says Ryan Manriquez, president of the UC ...

But Spinraza costs $750,000 in the first year of ... oral administration method will give it a competitive edge. The FDA approved Evrysdi for the treatment of spinal muscular atrophy (SMA ...

The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted Biogen’s applications for a higher dose regimen of spinal muscular atrophy (SMA) treatment Spinraza ...

The US Food and Drug Administration (FDA) on Friday (December 23 ... A clinical trial earlier this year demonstrated that the treatment, Spinraza (nusinersen) can improve survival and allow infants to ...

The FDA has started a priority review of Roche ... to be approved for SMA after Biogen’s blockbuster antisense drug Spinraza (nusinersen) – which became the first drug to treat the muscle ...

The global antisense oligonucleotides market is poised for remarkable growth over the next decade, projected to rise from USD 2,913.5 million in 2023 to USD 5,519.6 million by 2033, according to ...

Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company ... compared to the approved nusinersen regimen (SPINRAZA®).

Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease ...

The company has developed FDA-approved drugs, such as SPINRAZA for spinal muscular atrophy, TEGSEDI and WAYLIVRA for rare genetic disorders, and TRYNGOLZA for familial chylomicronemia syndrome (FCS).